Skip to main content
SpringerLink
Log in

Combination effect of meropenem with aminoglycosides and teicoplanin onPseudomonas and enterococci

Kombinationswirkung von Meropenem mit Aminoglykosiden oder Teicoplanin aufPseudomonas und Enterokokken

  • Addendum
  • Published:
Infection Aims and scope Submit manuscript

Summary

Thein vitro activity of meropenem, a new carbapenem, and the combination effect with netilmicin, tobramycin, gentamicin, and teicoplanin againstPseudomonas spp. and enterococci was studied. Meropenem showed very goodin vitro activity againstPseudomonas aeruginosa (MIC90 2 mg/l) and good to moderate activity againstPseudomonas putida (MIC90 4 mg/l) andEnterococcus faecalis (MIC90 8 mg/l). Aminoglycosides were highly active againstP. putida (MIC90 0.5 mg/l), but showed only moderate activity againstP. aeruginosa. The synergistic effect of meropenem was shown in combination with teicoplanin againstE. faecalis (40%). NoPseudomonas strains were inhibited by the synergistic effect of meropenem with aminoglycosides. No antagonism occurred with any of the combinations.

Zusammenfassung

In der vorliegenden Studie wurde dieIn-vitro-Aktivität von Meropenem, einem neuen Carbapenem und die Kombinationswirkung dieser Substanz mit Teicoplanin und den Aminoglykosiden Netilmicin, Tobramycin und Gentamicin gegenPseudomonas spp. und Enterokokken untersucht. Meropenem zeigte eine hoheIn-vitro-Wirksamkeit gegenPseudomonas aeruginosa (MHK90 2 mg/l); eine gute bis mäßige Aktivität zeigte die Substanz gegenPseudomonas putida undEnterococcus faecalis (MHK90 Werte zwischen 4 und 8 mg/l). Aminoglykoside wiesen eine sehr gute Aktivität gegenP. putida (MHK90 0,5 mg/l) und eine mäßige Aktivität gegenP. aeruginosa auf (MHK90 Werte zwischen 2 und 16 mg/l). Ein synergistischer Effekt der Meropenem-Teicoplanin-Kombination wurde bei 40% derE. faecalis-Stämme beobachtet, wobei keinPseudomonas-Stamm synergistisch von der Kombination Meropenem und Aminoglykoside inhibiert wurde. Eine antagonistische Wirkung konnte bei keiner der untersuchten Kombinationen festgestellt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jones, R. N., Barry, A. L., Thornsberry, C. In-vitro studies of meropenem. J. Antimicrob. Chemother. 24 (Suppl. A) (1989) 9–29.

    Google Scholar 

  2. Chanal, C., Sirot, D., Chanal, M., Cluzel, M., Sirot, J., Cluzel, R. Comparativein-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum β-lactamases. J. Antimicrob. Chemother. 24 (Suppl. A) (1989) 133–141.

    Google Scholar 

  3. Garcia-Rodrigez, J. A., Garcia-Sanchez, J. E., Garcia-Garcia, M. I., Garchia-Sanchez, E., Munoz-Bellido, J. L. Antibiotic susceptibility profile ofXanthomonas maltophilia. In vitro activity of β-lactam/β-lactamase-inhibitor combinations. Diagn. Microbiol. Infect. Dis. 14 (1991) 239–243.

    Google Scholar 

  4. Moellering, R. C., Eliopoulos, G. M., Sentochnik, D. E. The carbapenems: new broad spectrum β-lactam antibiotics. J. Antimicrob. Chemother. 24 (Suppl. A) (1989) 1–7.

    Google Scholar 

  5. Sanders, C. C., Sanders, W. E. Emergence of resistance during therapy with the newer β-lactam antibiotics: role of inducible β-lactamases and implication for the future. Rev. Infect. Dis. 5 (1983) 639–648.

    Google Scholar 

  6. Morrison, A. J., Wenzel, R. P. Nosocomial urinary tract infections due to enterococcus: ten years experience at a university hospital. Arch. Intern. Med. 146 (1986) 1549–1551.

    Google Scholar 

  7. Terpenning, M. S., Zervos, M. J., Schaberg, D. R., Kaufmann, C. A. Enterococcal infections: an increasing problem in hospitalized patients. Infect. Control Hosp. Epidemiol. 9 (1988) 457–461.

    Google Scholar 

  8. Just, H. M., Philips, E., Bassler, M., Daschner, F. D. Combination effect of azthreonam with four aminoglycosides on nosocomial gram-positive cocci and non-fermenting gram-negative bacteria. Eur. J. Clin. Microbiol. 1 (1982) 371–378.

    Google Scholar 

  9. Zervos, M. J., Patterson, J. E., Edberg, S., Pierson, C., Kauffman, C. A., Mikesell, T. S. Single-concentration broth microdilution test for detection of high-level aminoglycoside resistance in enterococci. J. Clin. Microbiol. 24 (1987) 2443–2444.

    Google Scholar 

  10. Donnelly, J. P., Willemse, J. G., Horrevorts, A. M., De Pauw, B. E. The activity of meropenem, ceftazidime and other antibiotics against bacteremic isolates from granulocytopenic and other patients. Rev. Esp. Quimioterap. 5 (1992) 65–71.

    Google Scholar 

  11. Turano, A., Ravizzola, G.: In vitro activity of meropenem. 8th Mediterranean Congress of Chemotherapy (1992), abstr. no. 332.

Download references

Author information

Authors and Affiliations

  1. Institute of Environmental Medicine and Hospital Epidemiology, University Hospital of Freiburg, Hugstetterstr. 55, D-79106, Freiburg, Germany

    A. Kropec M. D., S. Lemmen, M. Wursthorn &  F. D. Daschner

Authors
  1. A. Kropec M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Lemmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Wursthorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. D. Daschner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kropec, A., Lemmen, S., Wursthorn, M. et al. Combination effect of meropenem with aminoglycosides and teicoplanin onPseudomonas and enterococci. Infection 22, 306–308 (1994). https://doi.org/10.1007/BF01739926

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01739926

Keywords

Search

Navigation